New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT07279428
Summary
This is a first-in-human study to test the safety, side effects, and early signs of effectiveness of a new drug called BL-M24D1. It is for adults with advanced or spreading gastrointestinal cancers and other solid tumors that have not responded to other treatments. The study will first find the safest dose and then expand to see how the drug affects the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.